Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Okairos AG
Three European biotechs have joined forces to develop and manufacture a simian adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.